$18.97
0.03% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Stock price

$18.97
+4.33 29.58% 1M
-16.03 45.80% 6M
+5.73 43.28% YTD
-1.87 8.97% 1Y
-6.48 25.46% 3Y
+5.47 40.52% 5Y
+1.97 11.59% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.57 3.10%
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

Key metrics

Market capitalization $581.75m
Enterprise Value $565.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.20
P/S ratio (TTM) P/S ratio 6.37
P/B ratio (TTM) P/B ratio 8.16
Revenue growth (TTM) Revenue growth 432.03%
Revenue (TTM) Revenue $91.28m
EBIT (operating result TTM) EBIT $-114.95m
Free Cash Flow (TTM) Free Cash Flow $-135.80m
Cash position $385.37m
EPS (TTM) EPS $-5.20
P/E forward negative
P/S forward 11.99
EV/Sales forward 11.67
Short interest 43.52%
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a AnaptysBio, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
75%
Hold
25%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
91 91
432% 432%
100%
- Direct Costs 2.40 2.40
1% 1%
3%
89 89
501% 501%
97%
- Selling and Administrative Expenses 38 38
1% 1%
42%
- Research and Development Expense 163 163
24% 24%
179%
-113 -113
27% 27%
-123%
- Depreciation and Amortization 2.40 2.40
1% 1%
3%
EBIT (Operating Income) EBIT -115 -115
27% 27%
-126%
Net Profit -145 -145
11% 11%
-159%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Neutral
GlobeNewsWire
10 days ago
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
Neutral
GlobeNewsWire
about one month ago
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our C...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 136
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today